Global Targeted Drugs for NSCLC Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Target EGFR
  • 1.4.3 Target ALK
  • 1.4.4 Target HER2
  • 1.4.5 Target ROS1
  • 1.4.6 Target BRAF
  • 1.4.7 Target MEK
  • 1.4.8 Target VEGFR2
  • 1.4.9 Target VEGF
  • 1.4.10 Target MET
• 1.5 Market by Application
  • 1.5.1 Global Targeted Drugs for NSCLC Market Share by Application (2014-2025)
  • 1.5.2 Squamous Cell Carcinoma of NSCLC
  • 1.5.3 Adenocarcinoma of NSCLC
  • 1.5.4 Large Cell Carcinoma of NSCLC
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Targeted Drugs for NSCLC Market Size
• 2.2 Targeted Drugs for NSCLC Growth Trends by Regions
  • 2.2.1 Targeted Drugs for NSCLC Market Size by Regions (2014-2025)
  • 2.2.2 Targeted Drugs for NSCLC Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Targeted Drugs for NSCLC Market Size by by Players
  • 3.1.1 Global Targeted Drugs for NSCLC Revenue by by Players (2014-2019)
  • 3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
• 3.2 Targeted Drugs for NSCLC Key Players Head office and Area Served
• 3.3 Key Players Targeted Drugs for NSCLC Product/Solution/Service
• 3.4 Date of Enter into Targeted Drugs for NSCLC Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Targeted Drugs for NSCLC Market Size by Type (2014-2019)
• 4.2 Global Targeted Drugs for NSCLC Market Size by Application (2014-2019)

5 United States

• 5.1 United States Targeted Drugs for NSCLC Market Size (2014-2019)
• 5.2 Targeted Drugs for NSCLC Key Players in United States
• 5.3 United States Targeted Drugs for NSCLC Market Size by Type
• 5.4 United States Targeted Drugs for NSCLC Market Size by Application

6 Europe

• 6.1 Europe Targeted Drugs for NSCLC Market Size (2014-2019)
• 6.2 Targeted Drugs for NSCLC Key Players in Europe
• 6.3 Europe Targeted Drugs for NSCLC Market Size by Type
• 6.4 Europe Targeted Drugs for NSCLC Market Size by Application

7 China

• 7.1 China Targeted Drugs for NSCLC Market Size (2014-2019)
• 7.2 Targeted Drugs for NSCLC Key Players in China
• 7.3 China Targeted Drugs for NSCLC Market Size by Type
• 7.4 China Targeted Drugs for NSCLC Market Size by Application

8 Japan

• 8.1 Japan Targeted Drugs for NSCLC Market Size (2014-2019)
• 8.2 Targeted Drugs for NSCLC Key Players in Japan
• 8.3 Japan Targeted Drugs for NSCLC Market Size by Type
• 8.4 Japan Targeted Drugs for NSCLC Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Targeted Drugs for NSCLC Market Size (2014-2019)
• 9.2 Targeted Drugs for NSCLC Key Players in Southeast Asia
• 9.3 Southeast Asia Targeted Drugs for NSCLC Market Size by Type
• 9.4 Southeast Asia Targeted Drugs for NSCLC Market Size by Application

10 India

• 10.1 India Targeted Drugs for NSCLC Market Size (2014-2019)
• 10.2 Targeted Drugs for NSCLC Key Players in India
• 10.3 India Targeted Drugs for NSCLC Market Size by Type
• 10.4 India Targeted Drugs for NSCLC Market Size by Application

11 Central & South America

• 11.1 Central & South America Targeted Drugs for NSCLC Market Size (2014-2019)
• 11.2 Targeted Drugs for NSCLC Key Players in Central & South America
• 11.3 Central & South America Targeted Drugs for NSCLC Market Size by Type
• 11.4 Central & South America Targeted Drugs for NSCLC Market Size by Application

12 International Players Profiles

• 12.1 Allergan
  • 12.1.1 Allergan Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Targeted Drugs for NSCLC Introduction
  • 12.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.1.5 Allergan Recent Development
• 12.2 Amgen
  • 12.2.1 Amgen Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Targeted Drugs for NSCLC Introduction
  • 12.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.2.5 Amgen Recent Development
• 12.3 ARIAD Pharmaceuticals (Takeda)
  • 12.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Targeted Drugs for NSCLC Introduction
  • 12.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development
• 12.4 Beacon Pharma Limited
  • 12.4.1 Beacon Pharma Limited Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Targeted Drugs for NSCLC Introduction
  • 12.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.4.5 Beacon Pharma Limited Recent Development
• 12.5 BeiGene
  • 12.5.1 BeiGene Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Targeted Drugs for NSCLC Introduction
  • 12.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.5.5 BeiGene Recent Development
• 12.6 Biocon
  • 12.6.1 Biocon Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Targeted Drugs for NSCLC Introduction
  • 12.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.6.5 Biocon Recent Development
• 12.7 Boehringer-Ingelheim
  • 12.7.1 Boehringer-Ingelheim Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Targeted Drugs for NSCLC Introduction
  • 12.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.7.5 Boehringer-Ingelheim Recent Development
• 12.8 Celgene Corporation
  • 12.8.1 Celgene Corporation Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Targeted Drugs for NSCLC Introduction
  • 12.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.8.5 Celgene Corporation Recent Development
• 12.9 Drug International Limted
  • 12.9.1 Drug International Limted Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Targeted Drugs for NSCLC Introduction
  • 12.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.9.5 Drug International Limted Recent Development
• 12.10 Fujifilm Kyowa Kirin Biologics
  • 12.10.1 Fujifilm Kyowa Kirin Biologics Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Targeted Drugs for NSCLC Introduction
  • 12.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2014-2019)
  • 12.10.5 Fujifilm Kyowa Kirin Biologics Recent Development
• 12.11 Genvio Pharma Limited
• 12.12 Hetero Drugs
• 12.13 ImClone Systems ‎(Eli Lilly)
• 12.14 Incepta Pharmaceuticals
• 12.15 Mylan
• 12.16 Novartis
• 12.17 Pfizer
• 12.18 Reliance Lifesciences
• 12.19 Roche
• 12.20 AstraZeneca
• 12.21 Cipla
• 12.22 Teva
• 12.23 OSI Pharmaceuticals
• 12.24 Glenmark Pharmaceuticals
• 12.25 Natco Pharma

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer